Abstract: In some embodiments, a gamma titanium aluminide alloy consists essentially of, in atomic percent, 38 to about 50% aluminum, 1 to about 6% niobium, 0.25 to about 2% tungsten, 0.01 to about 1.5% boron, up to about 1% carbon, optionally up to about 2% chromium, optionally up to about 2% vanadium, up to about 2% manganese, and the balance titanium and incidental impurities. In some embodiments, the gamma titanium aluminide alloy forms at least a portion of a gas turbine component. In some embodiments, a gamma titanium aluminide alloy, consists essentially of, in atomic percent, about 40 to about 50% aluminum, about 1 to about 5% niobium, about 0.3 to about 1% tungsten, about 0.1 to about 0.3% boron, up to about 0.1% carbon, up to about 2% chromium, up to about 2% vanadium, up to about 2% manganese, up to about 1% molybdenum, and the balance titanium and incidental impurities.

Abstract: In some embodiments, a gamma titanium aluminide alloy consists essentially of, in atomic percent, about 38 to about 50% aluminum, about 6% niobium, about 0.25 to about 2% tungsten, optionally up to about 1.5% boron, about 0.01 to about 1.0% carbon, optionally up to about 2% chromium, optionally up to about 2% vanadium, optionally up to about 2% manganese, and the balance titanium and incidental impurities. In some embodiments, the gamma titanium aluminide alloy forms at least a portion of a gas turbine component. In some embodiments, a gamma titanium aluminide alloy, consisting essentially of, in atomic percent, about 40 to about 50% aluminum, about 3 to about 5% niobium, about 0.5 to about 1.5% tungsten, about 0.01 to about 1.5% boron, about 0.01 to about 1.0% carbon, optionally up to about 2% chromium, optionally up to about 2% vanadium, optionally up to about 2% manganese, and the balance titanium and incidental impurities.

Abstract: A cell analyzer includes: a measuring portion which measures cells that are nuclear stained; a displaying portion which displays a histogram of a fluorescence intensity by using a result of the measurement by the measuring portion; and a determining unit which obtains a number of strong-area cells that are distributed in an area where the fluorescence intensity is stronger than normal cells, and which determines a malignancy grade of cancer based on the number of strong-area cells and the histogram.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is a nickel-based coating composition containing cobalt, chromium, aluminum, tantalum, and nickel. The coating composition has a three phase ?, ??, ? microstructure wherein at least 5 volume % of the coating composition is present in the ? phase. Also provided are coating systems containing the coating composition, articles having the coating composition or coating system, and methods for protecting nickel-based superalloy substrates using the coating composition or coating system.

Abstract: An apparatus and a method for diagnosing a tumor are provided. A histogram generating section generates a histogram from a result of a measurement of fluorescence intensity of a suspension produced from a target sample. The histogram indicates a relation between the fluorescence intensity and the number of cells. A determination section detects an S phase fluorescence intensity range corresponding to S phase cells based on the fluorescence intensity corresponding to a peak of the number of cells in the histogram, detects an abnormal fluorescence intensity range corresponding to tumor cells, based on a change in the number of cells in the S phase fluorescence intensity range, and performs a diagnosis of a tumor in the target sample based on an index of the number of cells in a range defined by excluding the abnormal fluorescence intensity range from the S phase fluorescence intensity range.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: Provided is a cell isolation instrument capable of smoothly performing a plurality of steps associated with isolation of cells, including gripping of a biological tissue, transferring of the biological tissue, and isolating of the biological tissue. A container has an opening. A sealing member seals the opening. A pair of pinching parts is connected to the sealing member, and the pair of pinching parts opens or closes by being pressed.

Abstract: A method of analyzing cells, the method comprising: measuring a number of cells which are nuclear stained, in a to-be-determined tissue, and acquiring a histogram showing a fluorescence intensity based on a result of the measurement; analyzing the histogram, and acquiring data of predetermined parameters; comparing the data of the parameters with first thresholds predetermined for the parameters, to perform a first cancer determination for each of the parameters on the to-be-determined tissue; performing a scoring process for each of the parameters, on a result of the first cancer determination for each of the parameters, to calculate scores of the parameters; and combining the scores of the parameters with one another, thereby performing a second cancer determination on the to-be-determined tissue.

Abstract: A cell analyzing apparatus includes: a histogram acquirer which is configured to perform measurement of a number of nuclear stained cells, and which, by using a result of the measurement, is configured to acquire a histogram indicating a fluorescence intensity; and an analysis controller which is configured to apply frequency analysis on data of the histogram acquired by the histogram acquirer, and which is configured to determine existence/nonexistence of cancer cells based on a result of the frequency analysis.

Abstract: A cell analyzing apparatus includes: a first histogram acquiring section which is configured to acquire a first histogram of fluorescence intensities by using a result of a measurement of a number of nuclear stained cells; a second histogram acquiring section which is configured to acquire a second histogram that is normalized based on a fluorescence intensity value indicating a maximum value of the first histogram; a determining section which is configured to determine whether cancer cells exist or not, based on one of the first histogram and the second histogram; and an outputting section which is configured to output a result of the determination performed by the determining section.

Abstract: Rhenium-free nickel based alloys are provided. More particularly, the alloys comprise preferred levels and ratios of elements so as to achieve good high temperature strength of both gamma matrix phase and gamma prime precipitates, as well as good environmental resistance, without using rhenium. When cast and directionally solidified into single crystal form, the alloys exhibit creep and oxidation resistance substantially equivalent to or better than rhenium-bearing single-crystal alloys. Further, the alloys can be processed by directional solidification into articles in single crystal form or columnar structure comprising fine dendrite arm spacing, e.g., less than 400 ?m, if need be, so that further improvements in mechanical properties in the articles can be seen.

Abstract: On the basis of revocation information of a certificate, information of a certification authority and of the certificate issued by the certification authority from a terminal device, and information of a cryptographic algorithm, validity of the certificate from the terminal device is determined.

Abstract: Provided is a means for inhibiting a function of CD69, whereby allowing suppression of an inflammatory response. That is, provided are: a composition for treating an inflammatory disease which includes an antibody that specifically recognizes a myosin regulatory light chain polypeptide (hereinafter abbreviated as Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits a result of an effect of coexistence of Myl with CD69; a method of treating an inflammatory disease, including administering, to a subject diagnosed as having an inflammatory disease, a therapeutically effective amount of the antibody; and a method of identifying a compound that inhibits a result of an effect of coexistence of Myl with CD69, and a method of identifying a candidate compound for treating an inflammatory disease, including selecting a compound that inhibits the result.

Abstract: A pipette member to be attachable to a container capable of accommodating a tissue and a liquid, is used for isolating cells from the tissue by stirring, and includes: a cylinder member which includes a first opening that is to be accommodated in the container, and a second opening that is to be connected to a cell isolation apparatus, and in which a passage for communicating the first opening with the second opening is defined; and a filter member which is disposed inside the cylinder member, and which separates the passage into a first part that includes the first opening, and a second part that includes the second opening.

Abstract: A cobalt-nickel base alloy is disclosed. The alloy includes, in weight percent: greater than about 4 % of Al, about 10 to about 20 % of W, about 10 to about 40 % Ni, about 5 to 20 % Cr and the balance Co and incidental impurities. The alloy has a microstructure that is substantially free of a CoAl phase having a B2 crystal structure and configured to form a continuous, adherent aluminum oxide layer on an alloy surface upon exposure to a high-temperature oxidizing environment. A method of making an article of the alloy includes: selecting the alloy; forming an article from the alloy; solution-treating the alloy; and aging the alloy to form an alloy microstructure that is substantially free of a CoAl phase having a B2 crystal structure, wherein the alloy is configured to form a continuous, adherent aluminum oxide layer on an alloy surface upon exposure to a high-temperature oxidizing environment.

Abstract: A cell analyzing apparatus includes: a first histogram acquiring section which is configured to acquire a first histogram of fluorescence intensities by using a result of a measurement of a number of nuclear stained cells; a second histogram acquiring section which is configured to acquire a second histogram that is normalized based on a fluorescence intensity value indicating a maximum value of the first histogram; a determining section which is configured to determine whether cancer cells exist or not, based on one of the first histogram and the second histogram; and an outputting section which is configured to output a result of the determination performed by the determining section.

Abstract: A method of bonding superalloys is provided. The method includes: aligning a first superalloy subcomponent having a gamma-prime solvus g?1 and a second superalloy subcomponent having a gamma-prime solvus g?2, with a filler material that includes at least 1.5 wt % boron disposed between the first and second superalloy subcomponents; performing a first heat treatment at a temperature T1, where T1 is above the solidus of the filler material and below the liquidus of the filler material; and performing a second heat treatment at a temperature T2, where T2 is greater than T1, and where T2 is greater than or equal to the lower of g?1 and g?2.

Abstract: A method of bonding superalloys is provided. The method includes: aligning a first superalloy subcomponent having a gamma-prime solvus g?1 and a second superalloy subcomponent having a gamma-prime solvus g?2, with a filler material that includes at least 1.5 wt % boron disposed between the first and second superalloy subcomponents; performing a first heat treatment at a temperature T1, where T1 is above the solidus of the filler material and below the liquidus of the filler material; and performing a second heat treatment at a temperature T2, where T2 is greater than T1, and where T2 is greater than or equal to the lower of g?1 and g?2.

Abstract: A cell isolation apparatus includes: a chamber body which includes a chamber into which tissue is to be introduced; an isolation member which is moved in the chamber and which is to collide with the tissue to isolate a cell; and a controlling portion which controls an operation of the isolation member in the chamber body.